On April 16, 2018, the FDA granted approval of the checkpoint immunotherapy combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®), as a first-line treatment option for intermediate- and poor-risk patients with advanced renal cell carcinoma
read more about at the CRI website:
Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer
From the Cancer Research Institute website:
https://www.cancerresearch.org/blog/february-2018/durvalumab-stage-iii-lung-cancer-fda-approval
On Friday, February 16, 2018, the FDA approved durvalumab (IMFINZI ®, AstraZeneca), an anti-PD-L1 checkpoint immunotherapy, for patients with unresectable, stage III non-small cell lung cancer (NSCLC) that hasn’t progressed after prior chemo-radiation treatment. Importantly, this approval covers patients regardless of their PD-L1 expression status.
Where to find us:
Chair of General Pathology and Immunology
School of Medicine, University of Insubria
Padiglione Biffi
Via Ottorino Rossi 9, 21100 Varese
Tel. + 39-348-3034698